In 2011 we did an annual ASCO highlight video reel of what to watch out for. Three phase 1…
W2W4 at SITC23 - 10 emerging areas to pay attention to in IO
Parsing cancer research hype at ESMO23
How the landscape in prostate cancer could change in the medium to long term
The evolving BMS-Celgene pipeline and what's coming next in new developmental twists
In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…
5 abstracts to watch out for at the ASCO22 meeting in Chicago
What to watch out for at AACR22 if you're interested in NK cells
Highlights from Day 1 of CART22, part 1
Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME
What's hot in early preclinical development to watch out for?
A new emerging IO target of interest caught out attention, now what?
Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?
Will CAR-NK cells follow CAR-T cell therapies and hit prime time?
Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco
As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative
What can we learn about gamma delta T cell cancer immunotherapy in China?
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
Can we make novel allogeneic cell therapies with γδ T cells? We find out!
Can γδ T cells be employed as a therapeutic against cancer?
TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020
